Eldorado Gold stock falls after announcing Foran Mining acquisition

Investing.com -- Peakstone Realty Trust (NYSE:PKST) stock surged 33% Monday after announcing it has entered into a definitive agreement to be acquired by a Brookfield Asset Management (NYSE:BAM) private real estate fund for $21.00 per share in cash.

The all-cash transaction values the industrial real estate investment trust at approximately $1.2 billion in enterprise value and represents a 34% premium to Peakstone’s closing price on January 30, 2026. The deal also offers a 46% premium to the company’s 30-day volume weighted average price and a 51% premium to its 90-day VWAP.

The acquisition comes shortly after Peakstone completed its strategic transformation into an industrial-only REIT in December 2025 by divesting all of its office properties. The company’s current portfolio consists of 76 industrial properties, including 60 industrial outdoor storage properties and 16 traditional industrial properties.

"We are pleased to enter into this agreement with Brookfield, which will deliver significant value to Peakstone shareholders," said Michael Escalante, Chief Executive Officer of Peakstone. "Following an offer from Brookfield, our Board of Trustees evaluated the proposed transaction with the assistance of external advisors and determined that it achieves the best value and other terms reasonably available for shareholders and is in the best interests of the Company."

The transaction, unanimously approved by Peakstone’s Board, includes a 30-day "go-shop" period expiring on March 4, 2026, during which the company may solicit alternative acquisition proposals. Peakstone has agreed to suspend its regular quarterly dividend until the deal closes or the agreement terminates.

The acquisition is expected to close by the end of the second quarter of 2026, subject to shareholder approval and other customary closing conditions. Upon completion, Peakstone will become a privately-held company and its shares will no longer trade on the New York Stock Exchange.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Beyond Inc. (NYSE:BBBY) stock jumped 6.9% on Monday after the company announced plans to acquire Tokens.com to establish a foundation for a unified investment and personal finance platform.

The acquisition aims to address what Beyond describes as a fragmented market for financial services by creating a one-stop solution for real estate and other real-world asset finance that bridges tokenized and traditional investing. The platform will be integrated with the company’s existing financial technology, insurance, and blockchain-based businesses.

Beyond, which owns Bed Bath & Beyond, Overstock, buybuy BABY, and a blockchain asset portfolio, will leverage its experience in tokenized assets as an early blockchain technology investor. The company maintains strategic investments in digital asset businesses including tZERO and GrainChain through its Medici portfolio.

The new platform is designed to give customers a consolidated view of their assets and interests, including ownership structure, estimated values, existing obligations, and liquidity options. It will support tokenization of qualifying securities and real-world assets, alongside asset-backed financing solutions for home purchases, refinancing, and home equity.

"Providing responsible, compliant liquidity pathways for homeowners and real-world asset holders is our strategy and long-term vision," said Marcus Lemonis, Executive Chairman and CEO of Beyond Inc.

The platform will utilize tZERO’s infrastructure for capital markets, tokenization, custody, and trading. It will also partner with Figure Technologies and Figure Markets to provide mortgages, home equity lines of credit, and other asset-backed lending solutions.

Beyond expects the Tokens.com platform to become operational by July 1, 2026, subject to closing and customary conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Norway stocks were lower after the close on Monday, as losses in the Media, Transport and Diversified Financials sectors led shares lower.

At the close in Oslo, the Oslo OBX lost 0.24%.

The best performers of the session on the Oslo OBX were Storebrand ASA (OL:STB), which rose 1.90% or 3.20 points to trade at 171.70 at the close. Meanwhile, DnB ASA (OL:DNB) added 1.52% or 4.20 points to end at 280.90 and Gjensidige Forsikring ASA (OL:GJFG) was up 1.31% or 3.60 points to 277.40 in late trade.

The worst performers of the session were Tomra Systems ASA (OL:TOM), which fell 2.03% or 2.60 points to trade at 125.50 at the close. SalMar ASA (OL:SALM) declined 1.92% or 11.00 points to end at 562.00 and Aker BP ASA (OL:AKRBP) was down 1.78% or 5.00 points to 276.40.

Falling stocks outnumbered advancing ones on the Oslo Stock Exchange by 156 to 105 and 16 ended unchanged.

Crude oil for March delivery was down 4.89% or 3.19 to $62.02 a barrel. Elsewhere in commodities trading, Brent oil for delivery in April fell 4.66% or 3.23 to hit $66.09 a barrel, while the April Gold Futures contract fell 2.18% or 103.55 to trade at $4,641.55 a troy ounce.

EUR/NOK was up 0.59% to 11.46, while USD/NOK rose 1.06% to 9.71.

The US Dollar Index Futures was up 0.68% at 97.52.

Investing.com – Israel stocks were higher after the close on Monday, as gains in the Insurance, Financials and Real Estate sectors led shares higher.

At the close in Tel Aviv, the TA 35 gained 1.14% to hit a new all time high.

The best performers of the session on the TA 35 were Teva Pharmaceutical Industries Ltd (TASE:TEVA), which rose 6.93% or 700.00 points to trade at 10,800.00 at the close. Meanwhile, Harel (TASE:HARL) added 6.03% or 860.00 points to end at 15,130.00 and Migdal Insurance (TASE:MGDL) was up 4.43% or 74.00 points to 1,744.00 in late trade.

The worst performers of the session were Nova (TASE:NVMI), which fell 7.60% or 11,700.00 points to trade at 142,300.00 at the close. Camtek Ltd (TASE:CAMT) declined 5.21% or 2,490.00 points to end at 45,330.00 and Navitas Petroleum LP Unit (TASE:NVPTp) was down 2.08% or 250.00 points to 11,790.00.

Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 247 to 229 and 72 ended unchanged.

Shares in Teva Pharmaceutical Industries Ltd (TASE:TEVA) rose to 5-year highs; gaining 6.93% or 700.00 to 10,800.00. Shares in Harel (TASE:HARL) rose to all time highs; up 6.03% or 860.00 to 15,130.00.

Crude oil for March delivery was down 5.05% or 3.29 to $61.92 a barrel. Elsewhere in commodities trading, Brent oil for delivery in April fell 4.79% or 3.32 to hit $66.00 a barrel, while the April Gold Futures contract fell 1.69% or 80.20 to trade at $4,664.90 a troy ounce.

USD/ILS was down 0.24% to 3.10, while EUR/ILS fell 0.69% to 3.66.

The US Dollar Index Futures was up 0.66% at 97.50.

Investing.com -- Novo Nordisk (NYSE:NVO) stock climbed mid-morning, paring earlier declines to trade flat after the company announced positive results from its REIMAGINE 2 trial for CagriSema in adults with type 2 diabetes.

The Danish pharmaceutical giant reported that CagriSema demonstrated superior HbA1c reduction of 1.91%-points compared to 1.76%-points with semaglutide alone. The combination therapy also achieved superior weight loss of 14.2% versus 10.2% with semaglutide after 68 weeks of treatment.

The phase 3 trial, which included 2,728 people with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor, showed that up to 43% of patients achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss with CagriSema at the 2.4 mg/2.4 mg dose.

"We are very pleased by the clinical profile of CagriSema in type 2 diabetes patients, including a confirmation of the very strong weight loss data seen with CagriSema in the obesity trials," said Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk.

The company noted that no weight loss plateau was observed at week 68 for CagriSema, suggesting continued effectiveness throughout the treatment period. The most common adverse events were gastrointestinal in nature, with the majority being mild to moderate and diminishing over time.

Following these results, along with previous findings from REIMAGINE 1 and REDEFINE 3 trials, Novo Nordisk plans to approach regulatory authorities to discuss the pathway for CagriSema in type 2 diabetes. The company had already submitted CagriSema for weight management to the US FDA in December 2025 based on earlier pivotal trials.

CagriSema combines cagrilintide, a long-acting amylin receptor agonist, with semaglutide, Novo Nordisk’s GLP-1 receptor agonist that has driven significant revenue growth for the company through its Ozempic and Wegovy products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Morgan Stanley downgraded Humana to Underweight from Equal-weight, warning that policy risks and the company’s 2026 Medicare Advantage bid strategy could slow its margin turnaround and pressure earnings into 2027.

The bank cut its price target to $174 from $262 after lowering estimates and factoring in additional profit risks.

It said the call is relative, arguing that positioning looks more compelling at peers such as UnitedHealth Group, CVS Health and Cigna amid broader disruption in managed care.

Morgan Stanley said a weaker-than-expected Medicare Advantage Advance Rate Notice adds a new policy overhang for the sector, with Humana disproportionately exposed given its focus on MA. The notice pointed to roughly flat benchmark reimbursement rates for 2027, compared with market expectations for a 3% to 5% increase. The bank estimated that, on an unmitigated basis, each 1% decline in the rate notice could translate into about 36% earnings pressure for Humana in 2027.

The bank also flagged risks tied to Humana’s 2026 bid strategy. Based on its proprietary benefit richness analysis, Morgan Stanley said Humana stood out as one of the few plans to expand Medicare Advantage prescription drug offerings, increasing benefits by 2.9% overall. That contrasted with a national average decline of about 9% as competitors moved to protect margins.

Humana’s benefit richness increased across both HMO and PPO plans, with the company rising to the second-richest PPO offering, an area Morgan Stanley described as less profitable and one that many rivals are deemphasizing. While consistent with Humana’s stated strategy, the bank questioned whether the company fully anticipated the scale of benefit cuts by competitors.

Morgan Stanley said early-quarter commentary points to sharper-than-expected enrollment declines at other insurers, raising the risk that Humana’s enrollment growth could exceed plan assumptions. That dynamic could leave the company with higher membership but weaker profitability, complicating its planned recovery.

Humana shares are down about 24% year to date and trade at roughly 10.3 times Morgan Stanley’s 2027 earnings estimate, near peer levels. Even so, the bank said the stock may be more expensive than it appears if profit risks in 2026 and 2027 materialize.